4th Chronic Kidney Disease Drug Development Summit

As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.

The 4th Chronic Kidney Disease Drug Development Summit is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca, Johnson & Johnson, Bayer, Boehringer Ingelheim, Novartis, Otsuka, Novo Nordisk, and many more, this is a conversation you cannot afford to miss.

From dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI, this is the only end-to-end forum presenting scientific advancements as actionable insights.

We hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope, albuminuria, and real-world evidence into innovative trial design.

Take a look at the event guide here.